Dr. Dan Peterson - Working to Turn the Tide for ME/CFS ProHealth Rituximab's soon to be generic status means Roche has no incentive to undertake expensive studies on its effects in CFS, and without those studies there's little hope insurance companies will cover the cost of the drug. Some people will be able to pay ... |
